DT-EQUIPMENT
DT Equipment ehf. (DTE) (www.dtequipment.com ), a leader in real-time intelligence from liquid metals and developer of next-generation analytics for metals production and processing, is pleased to announce the appointment of Mr. Diego Areces as Chief Commercial Officer (CCO). His hire marks the latest in a series of appointments designed to further strengthen the DTE executive team and ensure that the company has the strategic, commercial and technical capabilities required for the next stage of its growth.
Commenting on the new appointment, Karl Matthiasson, CEO of DTE said, “I am very pleased to welcome Diego to our expanding executive team. His vast industry knowledge and extensive commercial experience will be indispensable, and we are delighted to have him on board as we continue the next stage of our journey.”
Mr. Areces who has 25 years’ experience in the industrial automation field, joins DTE to lead its commercial activities after a long tenure at Schneider Electric, where he held the position of Industrial Automation Networks Leader, Mining, Minerals, and Metals President and Process Automation North Asia Hub Leader, responsible for driving growth, transformation, and innovation. He will focus on bringing DTE’s breakthrough innovations in the metals analytics field to market and developing strategic relationships with customers and significant stakeholders.
“I am thrilled to join DTE, a great team of talented professionals on its way to transform a whole industry thanks to its breakthrough innovation", added Mr. Areces, “It is clear from my decades of working in the metals processing field that DTE’s real-time analytics and intelligence capabilities represent a significant breakthrough which offers a genuine opportunity to transform the way producers operate. I am focused on maximizing growth, value, sustainability, safety, and efficiency for all stakeholders, developing strategic relationships, and deploying business-driven technology and innovation; I look forward to an exciting new phase where there are no limits to what we can accomplish.
Mr. Areces is one of the early precursors of Industry 4.0, leading the deployment of internet technologies in industrial devices during the early 2000s. He has been a safety and sustainability champion and a significant contributor to the digital transformation of global industrial customers.
Mr. Areces is a founding member of modbus.org, was a marketing chair of the Interface for Distributed Automation (IDA) organization and a member of the Development Partner Institute for Mining. He holds an MS in Electronic Engineering from the University of Buenos Aires, Argentina, and a CSS in Administration and Management from Harvard University, US.
Find out more about DTE’s real-time liquid metals intelligence solutions at www.dtequipment.com
###
About DT Equipment
DTE, based in Reykjavik, Iceland, is a leading innovator in the field of real-time intelligence from liquid metals, helping customers to maximize value, efficiency, safety and sustainability. DTE’s vision is to transform metals production and processing with next-generation sensors and analytics, driving digital transformation of the metals industry towards Industry 4.0, while contributing to the 1.5-degree challenge.
DTE’s solution range combines first-in-industry LP-LIBS™ (Liquid-Phase Laser-Induced Breakdown Spectroscopy) elemental analysis with a powerful machine learning cloud platform, delivering valuable intelligence and predictive insights from liquid metals across the entire value chain.
For more information, please visit www.dtequipment.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210215005203/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom